Oxiracetam
| Oxiracetam | |
|---|---|
 | |
| Molecular structure via molpic based on CDK |
| Rotamer [] | |
|---|---|
| Conformer structure via 3Dmol.js |
| Physical properties [] | |
|---|---|
| Molecular mass | 158.16 g/mol [1] |
| Predicted LogP | -2.2 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C6H10N2O3 [1] |
| IUPAC name | 2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetamide [1] |
| SMILES | C1C(CN(C1=O)CC(=O)N)O [1] |
| InChI | InChI=1S/C6H10N2O3/c7-5(10)3-8-2-4(9)1-6(8)11/h4,9H,1-3H2,(H2,7,10) [1] |
| InChIKey | IHLAQQPQKRMGSS-UHFFFAOYSA-N [1] |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 8 hours |
Oxiracetam (also known as CGP 21690E, ISF-2522, Oxiracetamum, CGP-21690E, Gnf-pf-1005, N06BX07, 4-Hydroxy-2-oxopyrrolidine-N-acetamide, Hydroxypiracetam, 4-Hydroxy-2-oxo-1-pyrrolidineacetamide or 1-Pyrrolidineacetamide, 4-hydroxy-2-oxo-) is a
Chemistry
Stereochemistry []
Oxiracetam is a racemic mixture of the enantiomers.
| Stereoisomerism |
|---|
| Stereoisomer enumberation with rdkit |
Druglikeness
Lipinski's rule of five
Oxiracetam matches Lipinski's rule of five.Pharmacology
ATC Classification
In the nervous system (N) oxiracetam acts as a stimulant (N06B), other psychostimulants and nootropic (N06BX), oxiracetam (N06BX07) and psychoanaleptic (N06).[1]Legal status []
- Australia: Oxiracetam is a S4 substance.
- United States: Oxiracetam is a Unscheduled substance.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 4626, Oxiracetam. Accessed June 11, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4626
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Oxiracetam. UNII: P7U817352G. Global Substance Registration System. Accessed June 11, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/P7U817352G